-The Hindu In the case of technologies with benefits and risks, it is important to have regulatory mechanisms which can help analyse them in an impartial manner It is 61 years since the beginning of new genetics based on the discovery of the double helix structure of the DNA molecule. It is also 31 years since the production of transgenic plants. The first patent for a living organism went to Dr. Anand...
More »SEARCH RESULT
Centre asks States for data on beggars -Aarti Dhar
-The Hindu Concerned over the glaring increase in the number of beggars across all major cities and towns in the country, the Centre is now focussing on preventing begging. To begin with, the Ministry of Social Justice and Empowerment has asked the States and Union Territories to inform the Centre about schemes and welfare measures taken by them to check beggary. No information on implementation "Although various State governments and Union Territories have enacted...
More »Video-recording of consent for clinical trials driving away subjects, SC told -Dhananjay Mahapatra
-The Times of India NEW DELHI: The new draft protocol for clinical trials of drugs, on the lines suggested by the Supreme Court, is making it difficult for global drug manufacturers to find subjects for testing new chemical compositions. The protocol has made it mandatory for companies intending to conduct human trials of drugs to video-record the free consent of patients to be part of the trial. It also mandates them to...
More »Questions about India’s drug industry-Narayan Lakshman
-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...
More »Supreme Court blocks 157 clinical trials, says must follow new regime -Utkarsh Anand
-The Indian Express The fate of 157 government-approved global clinical trials seemed uncertain on Monday as the Supreme Court ordered the Centre to wait for its nod while the authorities re-examined the cases under the new regulatory regime. Making it clear that clinical trials being conducted in India must be done for the benefit of the people here, a bench of Justices R M Lodha and S K Singh directed the government...
More »